AMGN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 15.36
- PEG ratio
- 2.26
- P/B
- 20.06
- P/S (TTM)
- 4.95
- EV/EBITDA
- 13.78
Profitability & growth
- ROE (TTM)
- 101.3%
- Operating margin
- 33.8%
- Revenue growth YoY
- 5.8%
- Dividend yield
- 2.8%
- Beta
- 0.42
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
11 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Amgen Inc
Company profileAmgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
